Stockscreener 앱 받기
0.00
100.00%
-0.5266
전일 마감가:
$0.5266
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.56M
수익:
-
순이익/손실:
$-34.58M
주가수익비율:
0.00
EPS:
-11.69
순현금흐름:
$-26.63M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$9.88
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
명칭
Oncternal Therapeutics Inc
전화
(858) 434-1113
주소
12230 EL CAMINO REAL, SAN DIEGO, CA
ONCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCT
Oncternal Therapeutics Inc
|
0.00 | 1.56M | 0 | -34.58M | -26.63M | -11.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-07 | 개시 | Oppenheimer | Outperform |
| 2021-02-23 | 개시 | Northland Capital | Outperform |
Oncternal Therapeutics Inc 주식(ONCT)의 최신 뉴스
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - The AM Reporter
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Metastatic Prostate Cancer Market Future Business - openPR.com
Chronic Lymphocytic Leukemia Pipeline Analysis and Clinical - openPR.com
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewswire
From Nasdaq to Dark: What's Next for Oncternal After March 2025 Delisting? - StockTitan
B-Cell Non-Hodgkin Lymphoma Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Ewing Sarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
3 Top Tech Stocks to Buy Right Now - The Globe and Mail
Oncternal Therapeutics (ONCT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, - openPR
Billionaire Investor David Tepper Doubles Down on These Stocks. Should You Follow? - The Globe and Mail
Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Metastatic Prostate Cancer Clinical and Non-Clinical Studies, - openPR
Head-To-Head Survey: Oncternal Therapeutics (NASDAQ:ONCT) & Organigram (NASDAQ:OGI) - Defense World
Future-Proofing Growth of Metastatic Prostate Cancer Market, - openPR
IBM Stock 2025 Outlook: Can AI and Cloud Revive IBM’s Growth? - The Globe and Mail
StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
B-cell Lymphoma Pipeline Update 2024: FDA Approvals, - openPR
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Marketscreener.com
CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan
ONCT stock touches 52-week low at $0.61 amid market challenges - Investing.com Australia
ONCT stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com
Oncternal shares to be delisted from Nasdaq - Investing.com
Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks
ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
Oncternal Therapeutics Inc (ONCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):